Compare Davita Inc (DVA) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs SpaceX — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while SpaceX trades at $133.98 (market cap $1.83T). The key difference: SpaceX is far larger — about 156.1× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| DVA | SPCX | |
|---|---|---|
Market Cap | $11.72B | $1.83T |
Sector | Health | Technology |
52-Week High | $240.96 | $202.09 |
52-Week Low | $103.87 | $108.27 |
Enterprise Value | $24.44B | $1.77T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
SpaceX (SPCX) trades at $133.11, up 15.83% in 24 hours, reclaiming its $135 IPO price amid bullish technical signals and positive analyst sentiment. The stock shows strong momentum with resistance near $140 and support at $121. Despite negative profitability margins and high valuation ratios, robust revenue growth and significant capital investments in AI and infrastructure signal long-term ambition. Recent news highlights a major chip plant investment and a new satellite launch contract, fueling investor optimism.
Outlook is cautiously optimistic with a consensus price target of $228.52, though risks include persistent losses, high capex, and competitive pressures. The stock offers growth potential driven by Starlink's performance and strategic expansions, but investors must weigh volatility and execution risks against bullish analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
